Long-term Extension to a Phase 2, Open-Label, Clinical Trial of Miravirsen Sodium in Null Responders to Pegylated-Interferon Alpha Plus Ribavirin in Subjects With Chronic Hepatitis C (CHC) Virus Genotype 1 Infection

Trial Profile

Long-term Extension to a Phase 2, Open-Label, Clinical Trial of Miravirsen Sodium in Null Responders to Pegylated-Interferon Alpha Plus Ribavirin in Subjects With Chronic Hepatitis C (CHC) Virus Genotype 1 Infection

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Sep 2017

At a glance

  • Drugs Miravirsen (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 23 Jul 2015 Planned End Date changed from 1 Jan 2017 to 1 Nov 2016, as reported by ClinicalTrials.gov (NCT02508090)
    • 23 Jul 2015 Planned End Date changed from 1 Jan 2017 to 1 Nov 2016, as reported by ClinicalTrials.gov (NCT02508090)
    • 23 Jul 2015 Planned primary completion date changed from 1 Jan 2017 to 1 Nov 2016, as reported by ClinicalTrials.gov(NCT02508090)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top